Kiora Pharmaceuticals, Inc.
KPRX
$2.55
-$0.04-1.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -24.03% | 9.39% | |||
| Gross Profit | 24.03% | -9.39% | |||
| SG&A Expenses | 10.58% | 0.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.84% | 4.56% | |||
| Operating Income | 4.84% | -4.56% | |||
| Income Before Tax | 66.26% | -1,062.83% | |||
| Income Tax Expenses | -- | -1.07% | |||
| Earnings from Continuing Operations | 62.89% | -24,415.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 62.89% | -24,415.30% | |||
| EBIT | 4.84% | -4.56% | |||
| EBITDA | 4.87% | -4.58% | |||
| EPS Basic | 62.94% | -25,304.84% | |||
| Normalized Basic EPS | 3.17% | -9.46% | |||
| EPS Diluted | 62.88% | -25,304.84% | |||
| Normalized Diluted EPS | 3.17% | -11.29% | |||
| Average Basic Shares Outstanding | 0.11% | -2.79% | |||
| Average Diluted Shares Outstanding | 0.11% | -4.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||